Afaxys, Inc. – Trademark Portfolio
Entity Type: 03
Afaxys, Inc. holds 97 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 89 filings in this category. The portfolio also extends into Class 10 (Medical Apparatus) across 4 Nice Classification classes. Currently, 18 trademarks are registered and 11 are pending. Notable registered marks include EMAPP, LYLEQ, AFAXYS, ECONTRA, and JASMIEL. The owner is based in Charleston, SC.
455 1/2 King Street
Charleston, SC 29403
Showing of trademarks Trademarks
Trademark Classifications
Afaxys, Inc.'s trademark portfolio spans 4 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Advertising; business management; business administration; office functions
Scientific and technological services; industrial analysis and research services
Frequently Asked Questions
How many trademarks does Afaxys, Inc. have?
Afaxys, Inc. has 97 U.S. trademarks filed with the USPTO. Of these, 18 registered, 11 pending, 61 abandoned, 7 cancelled.
What trademark classes does Afaxys, Inc. file in?
Afaxys, Inc. files trademarks across 4 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus), Class 35 (Advertising & Business), Class 42 (Computer & Scientific). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are Afaxys, Inc.'s most well-known trademarks?
Afaxys, Inc.'s registered trademark portfolio includes well-known marks such as EMAPP, LYLEQ, AFAXYS, ECONTRA, and JASMIEL. These are among 18 currently registered trademarks in the portfolio.
What is Afaxys, Inc.'s trademark registration success rate?
Afaxys, Inc. has a 21% trademark registration rate, with 18 out of 86 resolved applications resulting in successful registration. Currently, 11 applications are pending review.